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Abstract: The 16p11.2 microdeletion syndrome is characterized by a wide range of phenotypic 
expressions and is frequently associated with developmental delay, symptoms from the autism 
spectrum, epilepsy, congenital anomalies, and obesity. These phenotypes are often related to a 
proximal 16p11.2 deletion of approximately 600 kb (BP4–BP5) that includes the SH2B1 gene 
that is reported to be causative for morbid obesity. This more centromeric deletion is most 
strongly related to autism spectrum susceptibility and is functionally different from the more 
distal 16p12.2p11.2 region, which includes the so-called atypical 16p11.2 BP2–BP3 deletion 
(approximately 220 kb) presenting with developmental delay, behavioral problems and mild 
facial dysmorphisms. Here, an adult male with a long history of maladaptive behaviors is 
described who was referred for diagnostic assessment of his amotivational features. Extensive 
neuropsychological examination demonstrated rigid thinking, anxious beliefs, and ideas of 
reference in the presence of normal intelligence. Microarray analysis demonstrated a de novo 
970 kb 16p11.2 BP1–BP4 microdeletion that can be regarded as explanatory for his behavioral 
profile. It is concluded that microdeletion syndromes are not exclusively related to intellectual 
disabilities and genetic testing is of putative relevance for the understanding of neuropsychiatric 
and neuropsychological phenomena.
Keywords: SNP array, microdeletion, distal 16p11.2, neuropsychological phenotype, social 
cognition
Introduction
Since high resolution comparative genomic hybridization techniques are increasingly 
available in the diagnostic procedures for patients with developmental disorders, 
several novel microdeletion and microduplication syndromes have been identified.1–3 
One of these is the 16p11.2 microdeletion syndrome (Online Mendelian Inheritance in 
Man [OMIM]: 611913). As reviewed by the research groups of Battaglia and Barge-
Schaapveld, the typical 16p11.2 microdeletion syndrome is characterized by a wide 
range of phenotypic expressions and is frequently associated with developmental delay, 
symptoms from the autism spectrum, epilepsy, congenital anomalies, and obesity.4,5 
These phenotypes are often related to a proximal 16p11.2 deletion of approximately 
600 kb (BP4–BP5) encompassing 29 genes,6–10 of which the SH2B1 gene (OMIM: 
608937) is reported to be causative for morbid obesity.11–13 Battaglia et al4 stated 
that this more centromeric deletion is most strongly related to autism spectrum 
susceptibility and is functionally different from the more distal region (16p12.2–
p11.2; OMIM: 613604) which includes the so called atypical 16p11.2 deletion 
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(approximately 220 kb) presenting with developmental delay, 
behavioral problems, and mild facial dysmorphisms.5
In the present paper, an adult male with a long history of 
maladaptive behaviors, later associated with recurrent mild 
depressive and autistic symptoms, is described; the patient 
was referred for reevaluation of his clinical picture, particu-
larly the amotivational features.
Patient and methods
Clinical description
The referred patient, a 33-year-old male, is the second son of 
non-consanguineous parents. He has a 5 years older, healthy 
brother. Apart from recurrent depression in his mother, there 
is no family history of intellectual disability, congenital 
anomalies, or neuropsychiatric disorders. The patient was born 
after an uncomplicated pregnancy and he had a normal birth 
weight and length (2,730 g and 48 cm, respectively; 0 standard 
deviation). No congenital anomalies were observed. There 
were normal developmental milestones. During early primary 
school years, both parents and teachers noticed social with-
drawal tendencies and, incidentally, disproportionate reactions 
like clownish and impulsive behaviors to minor social stress, 
especially in novel and unstructured situations. Aged 16, a 
preliminary diagnosis of pervasive developmental disorder 
was made by a remedial educationalist at a community men-
tal health center. Because of persistent behavioral problems, 
regularly accompanied by compelling and angry attitudes, 
secondary school education was fragmented; however, after 
several school changes, he finally completed high school at 
age 20. One year later, the patient discontinued his university 
studies because of problems with initiative and structuring of 
daily life. He was then admitted to a sheltered home facility. 
At the age of 24–25 years, marked motivational problems 
and recurrent mild depressive symptoms and/or ideas of ref-
erence necessitated several hospitalizations. Treatment with 
antidepressants and antipsychotics was given, without any 
effect. Ultimately, the patient was diagnosed with Asperger’s 
syndrome, a pervasive developmental disorder, and he was 
admitted to a specialized department for autism spectrum 
disorders. Neither somatic and neurological examination 
nor hematological and biochemical parameters disclosed any 
abnormalities. Electroencephalogram (EEG)-registration, 
magnetic resonance imaging (MRI), and dopamine trans-
porter – single photon emission computed tomography 
(DAT-SPECT) of the brain were all normal. The diagnosis 
of Asperger’s disorder was confirmed and the patient subse-
quently entered a specialized sheltered home facility.
present assessments
At the age of 32, he was referred for detailed reevalua-
tion of his persistent amotivational behavior, for which no 
explanation could be given. Therefore, apart from somatic 
and neurological reexamination, extensive neuropsychologi-
cal assessment including a Kaufman Adolescent and Adult 
 Intelligence Test (KAIT) and a Minnesota Multiphasic 
Personality Inventory 2 Restructured Form (MMPI-2-RF) 
restructured clinical scale profiling was performed,14,15 as well 
as high density resolution, genome-wide array analysis.
Results
At examination, no dysmorphic features were found. 
Somatic and neurological examination did not disclose any 
abnormalities. Length and weight were 183 cm and 80 kg, 
respectively.
Neuropsychological profile
The patient’s behavior showed autistic-like elements such as 
diminished social reciprocity, paucity of speech, poor prag-
matic language, and enhanced sensory perception. No major 
psychiatric symptoms could be detected. Neuropsychologi-
cal assessment revealed a KAIT14 total intelligence quotient 
of 112 and undisturbed attention, memory, and executive 
functioning. MMPI-2-RF testing15 disclosed poor reality test-
ing, marked feelings of distrust, and an anxious disposition 
with excessive worrying (Figure 1). This profile suggests an 
enhanced vulnerability to psychotic experiences.
affymetrix Cytoscan HD array
Genome wide array analysis with an average resolution of 
approximately 20 kb was performed using the Affymetrix 
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Figure 1 MMPI-2-RF restructured clinical scale profile of the patient with a de novo, 
approximately 970 kb interstitial deletion in 16p11.2.
Note: scale scores are uniform T scores.
Abbreviations: MMpI-2-rF, Minnesota Multiphasic personality Inventory 2 
restructured Form; rCd, Demoralization; rC1, somatic Complaints; rC2, Low 
positive emotions; rC3, Cynicism; rC4, antisocial Behavior; rC6, persecutory 
Ideation; rC7, Dysfunctional Negative emotions; rC8, aberrant experiences; rC9, 
Hypomanic activation.
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CytoScan HD array platform (Affymetrix Inc., Santa Clara, 
CA, USA) with 2.6 million markers, including 750,000 
genotype-able single nucleotide polymorphisms and 1.9 
million nonpolymorphic probes. The array results showed 
a 970 kb microdeletion in the short arm of chromosome 16. 
Subsequent carrier testing by array analysis in the parents 
revealed that the 16p11.2 microdeletion had occurred de 
novo in their child, resulting in the karyotype: arr[hg19] 
16p11.2(28,461,879-29,428,533)x1 dn. This novel 16p11.2 
BP1–BP4 microdeletion encompasses 20 known protein 
coding genes and two microRNAs (Figure 2).
Discussion
In the present paper, a 33-year-old, non-obese male with 
normal intelligence is described in whom a de novo, distal 
16p11.2 BP1–BP4 microdeletion was demonstrated; this 
microdeletion can be regarded as causative for his pattern of 
anxiety-driven withdrawal behaviors, which result in recur-
rent episodes with referential thoughts. At this moment, no 
losses of similar size have been reported in healthy individu-
als (Database of Genomic Variants; http://dgv.tcag.ca/dgv/
app/home).
So far, seven patients have been reported with a de novo 
microdeletion of 1.7–8.2 Mb in size, encompassing the 
16p11.2 region and including the distal 16p11.2 deletion; 
in contrast, in six other patients a de novo distal (previ-
ously called atypical) 16p11.2 deletion was demonstrated 
(Table 1). Recently, Guha and et al reported the results 
of a large association study with a cohort of 790 patients 
with schizophrenia spectrum disorders.16 They found 13 
patients with 16p11.2 deletions ranging from BP1–BP4 
which are not overlapping the proximal locus (BP4–BP5) 
that is connected to autism. This finding is in line with 
other copy-number variation studies and suggests this locus 
to be implicated in obesity and various neuropsychiatric 
disorders.12,17,18
The distal 16p11.2 deletion between BP1 and BP4, 
as reported here, encompasses 20 known protein-coding 
genes, ie, CLN3, APOBR, IL27, NUPR1, CCDC101, 
SULT1A2, SULT1A1, EIF3C, EIF3CL, ATXN2L, TUFM, 
SH2B1, ATP2A1, RABEP2, CD19, NFATC2IP, SPNS1, LAT, 
RRN3P2, and SNX29P2. Four of these are disease-causing 
genes: CD19 (OMIM: 107265); TUFM (OMIM: 602389); 
CLN3 (OMIM: 607042); and ATP2A1 (OMIM: 141750), 
without, however, any neuropsychiatric sequelae.
In conclusion, the distal 16p11.2 deletion phenotype is 
neither exclusively related to developmental delay nor to 
autism spectrum disorders. Rather, it has a highly variable 
presentation that may include, as demonstrated in the neu-
ropsychological profile of the present patient, high average 
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Figure 2 array plot of chromosome 16 and schematic representation of the distal 16p11.2 region.
Notes: (A) array plot of chromosome 16 of the patient with an interstitial deletion of 970 kb in 16p11.2 (red rectangle). (B) schematic representation of the distal region 
of 16p11.2. positions of genes and deletions are shown relative to the low copy repeat blocks within the 16p11.2 region (Bp1 through Bp5). The enlarged view of the distal 
16p11.2 region is a screen shot of the UCsC Genome Browser Build 37/hg19 (http://genome.ucsc.edu/).
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intelligence and social cognitive dysfunctions referring to 
Asperger’s syndrome.
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